Cinobufagin Enhances the Sensitivity of Cisplatin‐Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Guangxin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Second Hospital of Jilin University, Chang Chun, People's Republic of China. Hauptthemen laut MEDLINE: Bufanolides, Cisplatin, Antineoplastic Agents, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Health Commision Funds In China, National Natural Science Foundation of China, Natural Science Foundation of Jilin Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Lung cancer patients always develop serious chemotherapy resistance after long‐term use of cisplatin treatment. It has been demonstrated that the combination of cisplatin (DDP) with other chemotherapy drugs may significantly reduce drug resistance. Cinobufagin (CB) showed potent anti‐tumour effect against lung cancer. However, the relevance of CB and DDP resistance in lung cancer remains unclear. This article will study the effects of CB on reversing lung cell resistance. The apoptosis was rescued by flow cytometry analysis and TUNEL staining. The invasiveness was rescued by invasion assay. The mRNA and apoptosis‐related proteins were estimated by qRT‐PCR analysis and Western blot analysis, respectively. In vivo antitumor activities were investigated by subcutaneous xenograft assay. The present study firstly demonstrated that the sensitivity of DDP in DDP‐resistant A549 (A549/DDP) cells was enhanced when treated with CB. Moreover, CB combined with DDP weakened the proliferation and increased apoptosis of A549/DDP cells. In addition, the expression level of Bcl‐2 was increased, whereas Bax and caspase‐3 were activated when A549/DDP cells were treated with both drugs. After treatment with IGF1 or PMA and mixed drugs (CB + DDP), the expressions of P‐AKT, P‐PI3K, P‐MEK1/2 and P‐ERK1/2 were increased. Finally, the results of in vivo experiments showed that the combination of DDP and CB significantly reduced the growth of tumours derived from A549/DDP cells. The combination of CB and DDP can be considered an effective strategy to increase the sensitivity of DDP‐resistant lung cancer cells to DDP by inhibiting the PI3K/AKT and MAPK/ERK pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Second Hospital of Jilin University, Chang Chun, People's Republic of China.
- Department of Medical Research Center, Second Hospital of Jilin University, Chang Chun, People's Republic of China.
- College of Life Science, Jilin Normal University, Si Ping, People's Republic of China.
ORCID-Profile: Xin Li, Yicun Wang
Förderung
- Jilin Health Commision Funds In China
- National Natural Science Foundation of China
- Natural Science Foundation of Jilin Province
- Jilin Province Science and Technology Development Plan Item
Zitieren
APA
Zhang, G., Zhang, K., Li, X., Wang, X., Li, G., & Wang, Y. (2025). Cinobufagin Enhances the Sensitivity of Cisplatin‐Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70501
Vancouver
Zhang G, Zhang K, Li X, Wang X, Li G, Wang Y. Cinobufagin Enhances the Sensitivity of Cisplatin‐Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70501
BibTeX
@article{Zhang2025,
author = {Zhang, Guangxin and Zhang, Kun and Li, Xin and Wang, Xiuwen and Li, Guangquan and Wang, Yicun},
title = {Cinobufagin Enhances the Sensitivity of Cisplatin‐Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70501}
}
EUVIMED